New drug combo aims to shrink ovarian tumors in Hard-to-Treat patients
NCT ID NCT07339553
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests two oral drugs, zeprumetostat and fuzuloparib, in 30 people with advanced or recurrent ovarian cancer who do not have BRCA gene mutations. The goal is to see if the combination can shrink tumors and delay progression. Participants first take fuzuloparib alone, then both drugs together until the disease worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zeprumetostat and Fuzuloparib (two oral drugs)
What this could lead to
If it works, this could offer a new treatment option for people with advanced or recurrent ovarian cancer who have not responded to standard therapies.
What could go wrong
This is an early phase 2 trial with only 30 participants, so results may not apply to everyone. The combination may cause side effects like blood toxicity, and it is not yet known if it improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIANCANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••